

different sub-groups of persons with obesity. This study aimed to investigate the potential impact if such levels of weight loss could be achieved nationally and the cost implications.

The study used NCDMod [2], a microsimulation model that simulates inter-relationships of risk factors (including obesity), chronic disease and health system costs. NCDMod operates in 5 year cycles projecting to 2030. The main scenario simulated 20% of potential patients with obesity achieving their target weight loss and maintaining weight loss for the 15 year simulation. Sensitivity analysis was done including addition of drop-out/failure to lose weight despite starting treatment as set out by the obesity management algorithm. Key health outcomes were: Decrease in body mass index, cardiovascular disease events averted, quality adjusted life years gained and health system cost offsets.

In comparison to weight trajectories remaining at historical levels, implementation of the Obesity Management Algorithm estimates almost 500,000 less persons with obesity in 2030, resulting in a cost offset in the health system over the 15 years to 2030 of Au\$12.7 billion to potentially fund the required weight management programs. Even assuming that 40% of those that start the program either drop-out or fail to lose weight, there still would be 280 000 less persons with obesity in 2030 providing health system cost-offsets of Au\$7.7 billion.

The need to facilitate multifaceted, intensive weight management programs described in The Australian Obesity Management Algorithm is illustrated in this simulation, showing the potential decrease in persons with obesity over time and the freeing of health system funding to pay for such services.

References

- [1] Australian Bureau of Statistics. National Health Survey: First Results, 2014–15. Canberra Australia. ABS 2015.
- [2] Lymer S, Schofield D, Lee C, Colagiuri S. NCDMod: A Microsimulation Model Projecting Chronic Disease and Risk Factors for Australian Adults. *International Journal of Microsimulation* 2016;9:103–39.

<https://doi.org/10.1016/j.orcp.2018.11.036>

32

The role of the pro-apoptotic protein BIM in glucose homeostasis and preservation of islet mass in type 2 diabetes



Helen Thomas

St Vincent's Institute, Fitzroy, VIC, Australia

Abstract not available.

<https://doi.org/10.1016/j.orcp.2018.11.037>

33

IL-22-based tissue-targeted therapeutics for type 2 diabetes



Michael McGuckin

University of Melbourne, Parkville, VIC, Australia

Abstract not available.

<https://doi.org/10.1016/j.orcp.2018.11.038>

34

The interplay between insulin and the NPY system



Kim Loh

St. Vincent's Institute of Medical Research, Fitzroy, VIC, Australia

Insulin has been shown to have effects not only in the peripheral tissues, but also in the brain particularly in the arcuate nucleus of the hypothalamus to regulate glucose and energy homeostasis. The importance of the central neuropeptide Y (NPY) system in the regulation of appetite and energy metabolism is well established. Although insulin is known to influence NPY expression, the precise physiological role of insulin action in these neuronal cells remains unknown. A closely related peptide, PYY released from L-type cells of the gut, is also expressed in α -cells in the pancreatic islets. It has been shown that application of PYY decreases glucose stimulated insulin secretion from rat and mouse islets. PYY can activate Y1, Y2 and Y5 receptor to regulate feeding and energy balance, however, little is known as to which Y receptor(s) mediate PYY's effect in the pancreatic islets. We have recently identified that the Y1 receptors are expressed in the β -cells both in mice and humans. In this presentation, I will discuss the role of insulin action in NPY-expressing neurons and provide evidence addressing the role of Y1 receptor in the regulation of β -cell function and how inhibition of this receptor could improve islet transplantation outcome.

<https://doi.org/10.1016/j.orcp.2018.11.039>

35

Cafeteria diet-induced cognitive impairment is prevented by oral minocycline in association with changes in the microbiome



Sarah-Jane Leigh^{1,*}, Nadeem O. Kaakoush¹, Fred Westbrook², Margaret J. Morris¹

¹ *School of Medical Sciences, UNSW Sydney, Kensington, New South Wales, Australia*

² *Psychology, UNSW Sydney, Kensington, New South Wales, Australia*

Obesogenic diets and obesity are associated with cognitive impairment in both humans and animals. While the underlying mechanisms remain controversial, a key potential driver is increased inflammatory signalling associated with obesity. The anti-inflammatory antibiotic minocycline hydrochloride has been routinely used to depress microglial activity as it easily crosses the blood brain barrier. We used a rodent model to test the hypothesis that minocycline would alleviate the cognitive impairment produced by a high-fat high-sugar "cafeteria" diet. The study was a 2 × 2 design, where rats were exposed to either vehicle (syrup) or minocycline (40 mg/kg/day) while consuming either regular chow or cafeteria diet. Memory was tested using novel object and place recognition tasks (NOR and NPR, respectively) and EchoMRI determined body composition across 6 weeks of intervention. Rats fed the cafeteria diet and vehicle were impaired on the hippocampal-dependent NPR at 2, 4 and 6 weeks but minocycline administration spared NPR performance in cafeteria-fed rats (similar exploration ratios as chow and vehicle). Of interest, chow rats treated with minocycline performed worse than those treated with vehicle. Cafeteria-fed rats irrespective of drug treatment consumed 150% more energy over the experiment and gained 100% more fat mass relative to rats fed chow. Faecal microbiota alpha diversity was reduced by both cafeteria diet and minocycline,